NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

11336	Companies
251966	Keywords
181326	Articles
137788	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 10/31/2025 at 08:00, 1 year ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix announces $71M strategic royalty monetization agreement with Healthcare Royalty, extending cash runway and enabling long-term growth in cancer treatment

Cancer Treatment HealthCare Royalty Financial Agreement NANOBIOTIX Royalty Monetization
PRESS RELEASE

published on 10/31/2025 at 08:00, 1 year ago

NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable
Nanobiotix annonce un accord stratégique de 71 millions de dollars avec HealthCare Royalty pour étendre son horizon de trésorerie et soutenir la croissance à long terme

Croissance Financement Accord Stratégique HealthCare Royalty NANOBIOTIX
BRIEF

published on 10/01/2025 at 22:20, 1 year 1 month ago

NANOBIOTIX Reveals Promising Phase 1 Study Results for Esophageal Cancer Treatment

Phase 1 Study Radiotherapy Adverse Events JNJ-1900 (NBTXR3) Esophageal Cancer
BRIEF

published on 10/01/2025 at 22:20, 1 year 1 month ago

NANOBIOTIX révèle des résultats prometteurs d'une étude de phase 1 pour le traitement du cancer de l'œsophage

Étude De Phase 1 Radiothérapie JNJ-1900 (NBTXR3) Cancer De L'œsophage Événements Indésirables
PRESS RELEASE

published on 10/01/2025 at 22:15, 1 year 1 month ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
PRESS RELEASE

published on 10/01/2025 at 22:15, 1 year 1 month ago

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Nanobiotix annonce les premières données de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage. Taux de contrôle de la maladie de 85% et taux de réponse objective de 69%

NANOBIOTIX Phase 1 JNJ-1900 ASTRO Cancer De L’œsophage
PRESS RELEASE

published on 09/30/2025 at 22:27, 1 year 1 month ago

RAPPORT FINANCIER SEMESTRIEL
BRIEF

published on 09/30/2025 at 22:20, 1 year 1 month ago

Nanobiotix : Bilan financier et avancées cliniques au 1er semestre 2025

Résultats Financiers Biotechnologie NANOBIOTIX Johnson & Johnson JNJ-1900
BRIEF

published on 09/30/2025 at 22:20, 1 year 1 month ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 1 year 1 month ago

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
Nanobiotix fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025, marqué par le développement clinique de JNJ-1900 et une gestion financière rigoureuse

Résultats Financiers Développement Clinique Gestion Financière NANOBIOTIX JNJ-1900

Accesswire

Published on 11/14/2026 at 12:56, 12 hours 18 minutes ago

Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 23 hours 44 minutes ago

NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day ago

BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day ago

American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 1 hour ago

SLAM Announces Proposed Extension of Warrant Expiry Dates

View all ACCESSWIRE

EQS Group

Published on 11/13/2026 at 23:24, 1 day 1 hour ago

EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 3 hours ago

EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:15, 1 day 5 hours ago

Increase in Equity to Accelerate Growth
Published on 11/13/2026 at 19:08, 1 day 6 hours ago

EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 6 hours ago

Assemblée générale ordinaire des actionnaires le 18 décembre 2026

Les Echos

Published on 11/13/2026 at 17:45, 1 day 7 hours ago

STEF : Droits de vote au 31-10-2026
Published on 11/13/2026 at 11:35, 1 day 13 hours ago

ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 1 day 13 hours ago

ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 1 day 17 hours ago

Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 2 hours ago

Belgrano continues the implementation of its public share buyback offer (OPRA)

View all LES ECHOS COMFI WIRE